KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Gross Profit: 2010-2025

Historic Gross Profit for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $145.2 million.

  • Emergent BioSolutions' Gross Profit fell 15.19% to $145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $834.9 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $767.6 million for FY2024, which is 3.21% up from last year.
  • Per Emergent BioSolutions' latest filing, its Gross Profit stood at $145.2 million for Q3 2025, which was up 96.22% from $74.0 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Gross Profit ranged from a high of $534.3 million in Q4 2022 and a low of $11.4 million during Q1 2023.
  • In the last 3 years, Emergent BioSolutions' Gross Profit had a median value of $146.2 million in 2023 and averaged $190.6 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Gross Profit slumped by 94.92% in 2023, and later soared by 1,266.67% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Gross Profit (Quarterly) stood at $292.4 million in 2021, then surged by 82.73% to $534.3 million in 2022, then fell by 8.05% to $491.3 million in 2023, then decreased by 1.89% to $482.0 million in 2024, then declined by 15.19% to $145.2 million in 2025.
  • Its Gross Profit stands at $145.2 million for Q3 2025, versus $74.0 million for Q2 2025 and $133.7 million for Q1 2025.